Citations

Clear

13565 citation(s) found for "_, _".

Classic Papers in UrologyGerharzE.W., EmbertonM. and O’BrienT.: Classic Papers in Urology. Oxford: Isis Medical Media Ltd.1999. 360 pages.
Novicki, Donald E.

Mayo Clinic

Journal of Urology | November 18, 2003 | Volume: 165 | Issue: 2 | Pages: 732-732

10.1097/00005392-200102000-00102 Get It

Moment generation in wheelchair propulsion
Zhao, Kristin D. , Su, Fong‐Chin , An, Kai‐Nan , Guo, Lan-Yuen , Trentadue, Taylor P

Mayo Clinic

Proceedings of the Institution of Mechanical Engineers, Part H: Journal of Engineering in Medicine | November 18, 2003 | Volume: 217 | Issue: 5 | Pages: 405-414

10.1243/095441103770802577 | PMID 14558653 Get It

Wheelchair propulsion is a man-machine interaction in which chair design and fit affect the relative positions and orientations of the upper extremity relative to the handrim and wheel axle. To understand these relationships better, experimental data were collected in five hand positions from five subjects exerting maximal effort to propel an instrumented wheelchair with its wheel in a locked position. The results of experiments revealed that the progression moment was greater at both initial and terminal propulsion positions and smaller in the mid-propulsion position. The vertical and horizontal force components were directed radially away from the wheel axle posterior to the dead centre position and radially towards the wheel axle anterior to top dead centre. Subsequently, a subject-specific quasi-static model of the upper extremity which maximized wheel progression moment was developed to augment our understanding of experimental measures. Model-predicted trends in progression moments and hand force direction were similar to experiment. Model predictions revealed that the optimal progression moment generation could potentially be affected by an individual's anthropometric parameters, joint strengths and also the direction of force applied by the hand on the handrim. Through wheelchair fitting and training of wheelchair users, it may be possible to improve propulsion technique.
Obesity, Sleep Apnea, and Hypertension
Wołk, Robert , Shamsuzzaman, Abu, Somers, Virend K.

Mayo Clinic

Hypertension | November 11, 2003 | Volume: 42 | Issue: 6 | Pages: 1067-1074

10.1161/01.hyp.0000101686.98973.a3 | PMID 14610096 Get It

Obesity has a high and rising prevalence and represents a major public health problem. Obstructive sleep apnea (OSA) is also common, affecting an estimated 15 million Americans, with a prevalence that is probably also rising as a consequence of increasing obesity. Epidemiologic data support a link between obesity and hypertension as well as between OSA and hypertension. For example, untreated OSA predisposes to an increased risk of new hypertension, and treatment of OSA lowers blood pressure, even during the daytime. Possible mechanisms whereby OSA may contribute to hypertension in obese individuals include sympathetic activation, hyperleptinemia, insulin resistance, elevated angiotensin II and aldosterone levels, oxidative and inflammatory stress, endothelial dysfunction, impaired baroreflex function, and perhaps by effects on renal function. The coexistence of OSA and obesity may have more widespread implications for cardiovascular control and dysfunction in obese individuals and may contribute to some of the clustering of abnormalities broadly defined as the metabolic syndrome. From the clinical and therapeutic perspectives, the presence of resistant hypertension and the absence of a nocturnal decrease in blood pressure in obese individuals should prompt the clinician to consider the diagnosis of OSA, especially if clinical symptoms suggestive of OSA (such as poor sleep quality, witnessed apnea, excessive daytime somnolence, and so forth) are also present.
Pneumatic Compression Boots, Lithotomy Stirrups, and Lower Limb Compartment Syndrome
Warner, Mark A. , Halliwill, John R.

Mayo Clinic

Anesthesiology | November 10, 2003 | Volume: 97 | Issue: 1 | Pages: 285-285

10.1097/00000542-200207000-00055 Get It

Frequency of Myocardial Infarction, Pulmonary Embolism, Deep Venous Thrombosis, and Death following Primary Hip or Knee Arthroplasty
Wood, Margaret, Mantilla, Carlos B. , Horlocker, Terese T. , Schroeder, Darrell R. , Brown, David , Berry, Daniel J. , Mantilla, Carlos B , Schroeder, Darrell

Mayo Clinic

Anesthesiology | November 10, 2003 | Volume: 96 | Issue: 5 | Pages: 1140-1146

10.1097/00000542-200205000-00017 | PMID 11981154 Get It

Background There is limited information about the frequency of perioperative complications after elective primary orthopedic total hip and knee arthroplasty in contemporary practice. The purpose of this study was to determine the frequency of clinically relevant myocardial infarction, pulmonary embolism, deep venous thrombosis, and death within 30 days after elective primary hip or knee arthroplasty treated according to contemporary perioperative management. Methods The authors examined the medical records of consecutive patients undergoing hip or knee arthroplasty at their institution in a 10-yr period. Prospectively collected databases were used to identify patients with the diagnosis of myocardial infarction, pulmonary embolism, deep venous thrombosis, or death using strict validation criteria and diagnostic-certainty categories. Results A total of 10,244 patients underwent primary total hip or knee arthroplasty in the period of study. Of these, 224 patients had one or more adverse events (overall event rate: 2.2%; myocardial infarction: 0.4%; pulmonary embolism: 0.7%; deep venous thrombosis: 1.5%; death: 0.5%). Most adverse events (myocardial infarction, pulmonary embolism, and death) increased in frequency with older age, particularly for patients aged 70 yr or older. Myocardial infarction occurred more frequently in male patients. There were no differences in the overall event frequency between types of procedure. However, pulmonary embolism was highest in patients undergoing bilateral knee operations. Conclusions The overall frequency of serious complications within 30 days after primary total hip or knee arthroplasty with contemporary practice was 2.2%. Accurate knowledge of the perioperative risks associated with widely performed elective operations can be used to implement management strategies that may further improve patient outcomes and decrease cost.
Osteogenesis Imperfecta, Perioperative Bleeding, and Desmopressin
Keegan, Mark T. , Whatcott, Brett D., Harrison, Barry

Mayo Clinic

Anesthesiology | November 10, 2003 | Volume: 97 | Issue: 4 | Pages: 1011-1013

10.1097/00000542-200210000-00039 | PMID 12357173 Get It

Experience with the MicroSeq D2 Large-Subunit Ribosomal DNA Sequencing Kit for Identification of Commonly Encountered, Clinically Important Yeast Species
Hall, Leslie, Wohlfiel, Sherri L., Roberts, Glenn D.

Mayo Clinic

Journal of Clinical Microbiology | November 6, 2003 | Volume: 41 | Issue: 11 | Pages: 5099-5102

10.1128/jcm.41.11.5099-5102.2003 | PMID 14605145 Get It

ABSTRACT Experience with a MicroSeq D2 large-subunit (LSU) ribosomal DNA (rDNA) sequencing kit for identification of yeast species commonly encountered in the mycology laboratory at Mayo Clinic is described here. A total of 131 isolates of yeasts recovered from clinical specimens were included in the study. Phenotypic methods used for initial identification included germ tube formation, urease production, microscopic morphological features on cornmeal agar, and an API 20C AUX system; all isolates were sequenced using a MicroSeq D2 LSU rDNA sequencing kit. Nucleic acid sequencing identified 93.9% of the isolates to the correct genus and species. A total of 100 of the isolates (representing 19 species of Candida ) were sequenced, and 98% gave results concordant with identifications made by the API 20C AUX system; distance scores ranged from 0 to 1.88%, with an average value of 0.23%. Candida dubliniensis was not included in the MicroSeq database and was identified as Candida albicans . A total of 32 isolates representing 9 other genera (including Cryptococcus , Filobasidium , Kloeckera , Malassezia , Pichia , Sporidiobolus , Rhodotorula , Zygosaccharomyces , and Trichosporon ) were included, and 81.3% showed concordant results when phenotypic and sequencing results were compared. Most discrepancies were attributed to the lack of inclusion of the species in the MicroSeq or API 20C AUX database. The MicroSeq D2 LSU rDNA sequencing kit appears to be accurate and useful for the identification of yeasts that might be seen in a clinical laboratory.
Lung Epithelial Cells and Extracellular Matrix Components Induce Expression of Pneumocystis carinii STE20 , a Gene Complementing the Mating and Pseudohyphal Growth Defects of ste20 Mutant Yeast
Köhler, Julia R. , Thomas, Charles F., Fink, Gerald R. , Kottom, Theodore J. , Limper, Andrew H.

Mayo Clinic

Infection and Immunity | October 24, 2003 | Volume: 71 | Issue: 11 | Pages: 6463-6471

10.1128/iai.71.11.6463-6471.2003 | PMID 14573668 Get It

ABSTRACT Pneumocystis carinii causes severe pneumonia in immunocompromised hosts. The binding of P. carinii to alveolar epithelial cells and extracellular matrix constituents such as fibronectin and vitronectin is a central feature of infection, which initiates proliferation of the organism. Herein, we demonstrate that P. carinii binding to lung cells specifically alters the gene expression of the organism, regulating fungal growth. Subtractive hybridization was performed to isolate P. carinii genes expressed following binding to mammalian extracellular matrix constituents. P. carinii STE20 ( PCSTE20 ), a gene participating in mating and pseudohyphal growth of other fungi, was identified following adherence to the extracellular matrix constituents fibronectin, vitronectin, collagen, and lung epithelial cells. The expression of PCSTE20 and a related P. carinii mitogen-activated protein kinase (MAPK) kinase gene, also implicated in signaling of mating, were both specifically upregulated by binding to matrix protein. The expression of general cyclin-dependent kinases and other MAPKs not involved in mating pathways were not altered by organism binding. PCSTE20 expression was also strongly enhanced following organism attachment to A549 lung epithelial cells. When expressed in a Saccharomyces cerevisiae ste20Δ mutant, PCSTE20 suppressed defects in both mating and pseudohyphal growth. These findings are consistent with the observed proliferation and filopodial extension of Pneumocystis organisms adherent to the epithelium in the lungs of immunocompromised hosts. PCSTE20 expression appears to represent a significant component in the regulation of the life cycle of this intractable opportunistic pathogen.
Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival
Novak, Anne J. , Darce, Jaime, Arendt, Bonnie K., Harder, Brandon , Henderson, Kathy, Kindsvogel, Wayne, Gross, Jane A. , Greipp, Philip R., Jelinek, Diane F., Henderson, Kathy

Mayo Clinic

Blood | September 29, 2003 | Volume: 103 | Issue: 2 | Pages: 689-694

10.1182/blood-2003-06-2043 | PMID 14512299 Get It

Abstract Multiple myeloma (MM) is a progressive disease that is thought to result from multiple genetic insults to the precursor plasma cell that ultimately affords the tumor cell with proliferative potential despite its differentiated phenotype and resistance to undergoing apoptosis. Altered expression of antiapoptotic factors as well as growth factors have been described in a significant number of patients. However, the key regulatory elements that control myeloma development and progression remain largely undefined. Because of the knowledge that B-lymphocyte stimulator (BLyS), a tumor necrosis factor (TNF) family member shown to be critical for maintenance of normal B-cell development and homeostasis, promotes the survival of malignant B cells, we began a coordinated study of BLyS and its receptors in MM. All MM cells studied expressed one or more of 3 known receptors (B-cell maturation antigen [BCMA], transmembrane activator and CAML interactor [TACI], and B-cell activating factor receptor [BAFF-R]) for BLyS; however, the pattern of expression was variable. Additionally, we provide evidence that BLyS can modulate the proliferative capacity and survival of MM cells. Finally, we provide evidence that BLyS is expressed by MM cells and is present in the bone marrow of patients with MM. Expression of BCMA, TACI, and BAFF-R by MM taken together with the ability of BLyS to support MM cell growth and survival has exciting implications because they may be potential therapeutic targets.
Estrogen, Bone, and Osteoporosis
Riggs, B. Lawrence

Mayo Clinic

Science of Aging Knowledge Environment | September 23, 2003 | Volume: 2003 | Issue: 32 | Pages: No page available

10.1126/sageke.2003.32.tr2 Get It

Until 1995, scientists held five widely accepted pillars of belief about estrogen action in the skeleton. Since then, a sea change in conventional wisdom has swept away these five beliefs. This lecture reviews data that have proved them wrong--or at least incomplete--and describes the new paradigms that have emerged to replace them. [Presentation] References 1. B. L. Riggs, S. Khosla, L. J. Melton III, Sex steroids and the construction and conservation of the adult skeleton. Endocr. Rev. 23 , 279-302 (2003). [Abstract] [Full Text]